Aquestive Therapeutics, Inc. AQST Business Segments — Income Tax Expense (Benefit)

Similar metrics at other companies

APO

APOGReportable Segment — Income Tax Expense (Benefit)

$6.37M+2,407%

MAMAReportable Segment — Income Tax Expense (Benefit)

$577K+106%

TVTXReportable Segment — Income Tax Expense (Benefit)

-$120K-408%

PGNYReportable segment — Income Tax Expense (Benefit)

$12.65M+10.2%

REPXReportable Segment — Income Tax Expense (Benefit)

$22.29M+371%

PEBReportable Segment — Income Tax Expense (Benefit)

-$17K+99.5%

Questions, answered.

What is Aquestive Therapeutics, Inc.'s business segments — income tax expense (benefit)?

Aquestive Therapeutics, Inc. (AQST) reported business segments — income tax expense (benefit) of $0 in Q4 2025.

How has Aquestive Therapeutics, Inc.'s business segments — income tax expense (benefit) changed year-over-year?

Aquestive Therapeutics, Inc.'s business segments — income tax expense (benefit) increased by 100.0% year-over-year, from -$3.5K to $0.

What is the long-term trend for Aquestive Therapeutics, Inc.'s business segments — income tax expense (benefit)?

Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s business segments — income tax expense (benefit) has grown at a -100.0% compound annual growth rate (CAGR), from $245K to $0.

What does business segments — income tax expense (benefit) mean?

This metric reflects the total tax liability or benefit recognized by the reportable segment based on its pre-tax earnings or losses within the relevant jurisdictions. It highlights the tax efficiency of the segment's operations and the impact of tax credits or deferred tax assets on the segment's overall financial results. Monitoring this helps investors understand how regulatory and tax environments influence the segment's net contribution to the company's consolidated financial statements.